⚠️ Uptrend Under Pressure Severe risk · 99 · Institutional selling is building — 6 distribution days in the last 25 sessions. · 6 distribution days (SPY) Full briefing → Jul 28
Simple research view

BAX · Baxter International Inc.

$23.34 latest stored close
Detected setup watchlist_candidate

Watch · Quality 0/100

1 independent risk warning also present. Review before relying on the bullish setup.

Ask about BAX

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

Scans / Health Technology / BAX

$BAX

Baxter International Inc.

Baxter International Inc. is a large-cap Medical Specialties company in the Health Technology sector with a market cap of $12B.

Strong Buy · 85 Health Technology Medical Specialties stock Stage 2 · Advancing Base 1 Data 56m ago
$23.34 latest close
Council read · 6 methods

Watch — evidence is building

0 buyable · 4 watch · 2 avoid. Review the observed passes and blockers before reading the chart.

Earnings-risk mode

Pre-earnings setup

Thursday, July 30, 2026 Time not confirmed No sourced report session or clock time

Deterministic evidence

BAX+4.20%
Sector proxy · XLV+0.51%
Broad market · SPY+0.02%
Same completed session window ending 2026-07-27. BAX was +3.69 points vs XLV. +4.18 points vs SPY.
CatalystUnavailable Stock reactionPositive Sector reactionSupportive Opening surgeUnavailable Event riskEarnings-driven
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

AI interpretation (optional)

Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.

Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.
Price $23.34 Jul 27 close
52W High $29.35 -20.5%
52W Low $15.73
Wks Since High 50w
Base Depth -46.4%
Base B1
SMA 50 $20.62
SMA 200 $19.51
Avg Vol 6,360,803
RS Rank 36
RS vs High -31.1%
RS Slope +6.3% ▲
Grp Rank #47/64
ADR% 3.1%
ATR(14) $0.82 (3.5%)
Rel Vol (today) 0.86×
Vol Pace N/A
U/D Vol 0.80
A/D Days 20A / 15D
A/D Rating A+
VDU Bars 0/10 d
Power Trend 2d
Earnings 2d
$15.73
$29.35 56%

BAX Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for BAX.

Create Free Account
Setup Quality D 1/7 signals
Jul 24: 0 (watchlist_candidate)Jul 27: 0 (watchlist_candidate)Jul 28: 0 (watchlist_candidate)0 Score trend
✓ Stage 2 · Advancing ✗ Power Trend 2d ✗ RS New High ✗ Trend 5/8 ✗ No Pattern ✗ Gatekeeper Base #1 (A)

See the full conviction stack.

Unlock Insights

Technical Analysis Report Card

$BAX · $23.34 · as of 2026-07-27 · multi-factor read
85
/ 100
Strong Buy

Trend · Daily / Weekly / Monthly

Daily ▲ Uptrend
Weekly ▲ Uptrend
Monthly ▲ Uptrend

Moving Averages

50-day$20.62 ↑
100-day$19.03 ↑
200-day$19.51 ↑
Golden Cross (fresh)

RSI (14)

Reading62.0 · Bullish

Bullish momentum — comfortably in buyer territory.

MACD (12/26/9)

StateWeakening
Histogram-0.080

Weakening — MACD slipped below its signal line. Histogram expanding.

Bollinger Bands (20,2)

%B / Width98% · 9.7%
Squeeze — volatility compressing

Near the upper band — buyers in control. Bands are squeezing — volatility is compressing, often a precursor to a sharp move.

Volume · Buyer vs Seller

Up/Down vol0.8 · Neutral
Rel volume0.86×

Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.

Support & Resistance

R · $23.62swing level
R · $29.3552-week high
Price · $23.34now
S · $21.16swing level
S · $19.34swing level
S · $18.58swing level

Fibonacci · Uptrend swing

23.6%$21.83
38.2%$20.66
50.0%$19.72
61.8%$18.78
78.6%$17.44

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for BAX — plus the full 495-symbol scanner and Ask-the-Legends chat.
🔒 Start your 7-day free trial →
Daily uptrendWeekly uptrendMonthly uptrendAbove 200-day MA50/200 bullishRS 33 (laggard)
Want this read in a legend's voice? 💬 Ask a Legend about BAX
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 🟡 4 of 6 legends are Watching — building, not yet a confirmed buy.
Avoid
Minervini D

Trend-template read: fails 150-day MA > 200-day MA.

Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $23.34, MA150 $19.41, MA200 $19.51
1.4 50-day MA > 150-day MA AND 200-day MAMA50 $20.62, MA150 $19.41, MA200 $19.51
Failing evidence
1.2 150-day MA > 200-day MAMA150 $19.41 vs MA200 $19.51
1.8 RS rank ≥ 70 (prefer ≥ 85)RS rank 33
5/10 checks
Avoid
O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence
S: Base tightness (ATR% ≤ 4.5%)ATR% 3.50%
Failing evidence
C: Quarterly EPS acceleration ≥ 25%-18.2% QoQ
L: RS rank ≥ 80 (IBD leadership)RS rank 33
1/8 checks
Watch
Weinstein D

Stage-analysis read: Stage 2 is present; 3 supporting checks need improvement.

Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $23.34 vs MA200 $19.51
Failing evidence
Volume expansion above averageVolume ratio 0.86x
Relative strength ≥ 60RS 33
3/6 checks
Watch
Livermore B

Pivotal-point read: constructive evidence is present, but relative strength is unresolved.

Passing evidence
Price$23.34
Distance from 52-week high20.5% below high
Failing evidence
Relative strengthRS 33
Volume vs average0.86x
3/6 checks
Watch
Darvas B

Box-theory read: constructive evidence is present, but relative strength is unresolved.

Passing evidence
Price$23.34
Distance from 52-week high20.5% below high
Failing evidence
Relative strengthRS 33
Volume vs average0.86x
3/6 checks
Watch
Wyckoff B

Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.

Passing evidence
Price$23.34
Distance from 52-week high20.5% below high
Failing evidence
Relative strengthRS 33
Volume vs average0.86x
3/6 checks
Breakout Health

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising
71RS Line (52W)
Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +8 A+
A: 23 D: 15 Net: +865 sessions
Minervini · Grade Card
Fundamentals & leadership quality — Minervini SEPA criteria · 3/7 met
C 3/7 SEPA
Separate score from the 8-point Trend Template (5/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ -18%
Revenue growth ≥20% YoY +6%
Gross margin ≥30% 31%
ROE ≥17% -16%
RS rating ≥80 (leadership) 33
Stage 2 uptrend (Weinstein) Stage 2
Within 25% of 52W high -20.5%

Method Playbook

📋 Trade it like Weinstein EXACT LEVELS · PRO
Minervini O'Neil Livermore Weinstein Darvas Wyckoff
Weinstein D · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro level
Published-method rule: Use Stage 1 resistance and the rising 30-week moving average as the Stage 2 transition boundary.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro level
Published-method rule: Require a Stage 2 breakout above resistance on expanding volume; avoid entries while the 30-week average is flat or falling.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro level
Published-method rule: Start below the breakout structure or Stage 1 support where a return to the base invalidates the Stage 2 transition.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-based
Published-method rule: Trail beneath rising 30-week support or later higher swing lows while Stage 2 remains intact.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro level
Published-method rule: Exit on a decisive 30-week support failure or a Stage 3/Stage 4 transition; never treat a failed Stage 2 break as healthy consolidation.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis

RS Score 33
Trend 5/8
Why This Setup?
watchlist_candidate

Near-miss 5/8 — needs: sma150 above sma200, sma200 trending up, rs score above 70

The Universal Edge Check

The panel is uneasy

Too many universals unmet — this leans closer to a guess than a trade.

1/7 universals met
Why these seven? → The Universal Edge

Minervini Trend Template

5/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $23.34 vs SMA150 $19.41 / SMA200 $19.51
SMA 150 above SMA 200 SMA150 $19.41 vs SMA200 $19.51
SMA 200 trending up Slope -0.09 over 20 days
SMA 50 above SMA 150 & 200 SMA50 $20.62
Price above SMA 50 $23.34 vs SMA50 $20.62
30%+ above 52W low +48.4% from $15.73
Within 25% of 52W high -20.5% from $29.35
RS score above 70 RS 33

Fundamentals

52W Range
56%
Mkt Cap SEC
12.1B
EPS QoQ
-18%
Rev YoY
+6%
ROE
-16%
Gross Margin
31%
D/E
1.55
EPS TTM
$-1.87
Float
516M
Insider
No Buy

Company

Legend AI snapshot
Baxter International Inc.
BAX · NYSE · Health Technology · Medical Specialties
$23.34latest close $12.1Bmarket cap 36RS rank 0setup score

Scan History

20× streak
Jul 24: 0 (watchlist_candidate)Jul 27: 0 (watchlist_candidate)Jul 28: 0 (watchlist_candidate)0
Jul 28
watchlist_candidate
0
Jul 27
watchlist_candidate
0 0.0%
Jul 24
watchlist_candidate
0 +4.2%

Get the full picture on BAX

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.

Start 7-Day Free Trial